Chemical Compound

[1S-[1a[2S*,4S*[ssS*,dS*[1R*,2R*,6S*,8R*(R*)]]],2a,6ss,8d(R*)]]-1,2,6,7,8,8a-Hexahydro-.beta.,.delta.-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid 2-[[1,2,6,7,8,8a-Hexahydro-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1- naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl Ester; L 665624; Lovastatin EP Impurity D

CAS Registry Number 149756-62-7
[1S-[1a[2S*,4S*[ssS*,dS*[1R*,2R*,6S*,8R*(R*)]]],2a,6ss,8d(R*)]]-1,2,6,7,8,8a-Hexahydro-.beta.,.delta.-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid 2-[[1,2,6,7,8,8a-Hexahydro-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1- naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl Ester; L 665624; Lovastatin EP Impurity D 结构式
Primary record

[1S-[1a[2S*,4S*[ssS*,dS*[1R*,2R*,6S*,8R*(R*)]]],2a,6ss,8d(R*)]]-1,2,6,7,8,8a-Hexahydro-.beta.,.delta.-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid 2-[[1,2,6,7,8,8a-Hexahydro-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1- naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl Ester; L 665624; Lovastatin EP Impurity D

库存
2,590 克
纯度
99.6 %
CAS
149756-62-7

化合物标识与属性

CAS
149756-62-7
PubChem CID
71749741
SMILES
CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CCC3C[C@H](CC(=O)O3)OC(=O)C[C@@H](C[C@@H](CC[C@H]4[C@H](C=CC5=C[C@@H](C[C@@H]([C@H]45)OC(=O)[C@@H](C)CC)C)C)O)O)C
Canonical SMILES
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CCC3C[C@@H](OC(=O)C[C@H](O)C[C@H](O)CC[C@@H]4[C@@H]5C(=C[C@H](C)C[C@@H]5OC(=O)[C@@H](C)CC)C=C[C@@H]4C)CC(=O)O3)[C@H]21

名称与同义词

  • Lovastatin Dimer
  • Lovastatin EP Impurity D
  • Lovastatin Dimer (>90%)
  • 149756-62-7
  • DTXSID40857919
  • GZGUDHDMNATZDU-CRMSOXFQSA-N
  • FT-0670867
  • L 665624
  • [(4R)-2-[2-[(1S,2S,6R,8S,8Ar)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]ethyl]-6-oxooxan-4-yl] (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
  • [1S-[1alpha[2S*,4S*[betaS*,deltaS*[1R*,2R*,6S*,8R*(R*)]]],2alpha,6beta,8delta(R*)]]-1,2,6,7,8,8a-Hexahydro-.beta.,.delta.-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid 2-[[1,2,6,7,8,8a-Hexahydro-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1- naphthaleny
  • N-(2-(3-Mercapto-2-aminopropylamino)-3-methylpentyl)isoleucyl-homoserine
  • (2R,4R)-2-[2-[(1S,2S,6R,8S,8aR)-2,6-Dimethyl-8-[[(2S)-2-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]ethyl]-6-oxotetrahydro-2H-pyran-4-yl (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-[[(2S
  • (4R)-2-{2-[(1S,2S,6R,8S,8AR)-2,6-DIMETHYL-8-{[(2S)-2-METHYLBUTANOYL]OXY}-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL]ETHYL}-6-OXOOXAN-4-YL (3R,5R)-7-[(1S,2S,6R,8S,8AR)-2,6-DIMETHYL-8-{[(2S)-2-METHYLBUTANOYL]OXY}-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL]-3,5-DIHYDROXYHEPTANOATE
  • [1S-[1|A[2S*,4S*[|AS*,|AS*[1R*,2R*,6S*,8R*(R*)]]],2|A,6|A,8|A(R*)]]-1,2,6,7,8,8a-Hexahydro-.beta.,.delta.-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid 2-[[1,2,6,7,8,8a-Hexahydro-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl Ester
  • [1S-[1a[2S*,4S*[ssS*,dS*[1R*,2R*,6S*,8R*(R*)]]],2a,6ss,8d(R*)]]-1,2,6,7,8,8a-Hexahydro-.beta.,.delta.-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid 2-[[1,2,6,7,8,8a-Hexahydro-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1- naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl Ester; L 665624; Lovastatin EP Impurity D
  • 2-(2-(2,6-dimethyl-8-((2-methylbutanoyl)oxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)ethyl)-6-oxotetrahydro-2H-pyran-4-yl 7-(2,6-dimethyl-8-((2-methylbutanoyl)oxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)-3,5-dihydroxyheptanoate